Abstract: The present invention provides a method for the detection of testicular cancer and/or precursors hereof by screening a sample for the presence of at least two markers in the same cell, wherein the sample is a semen sample and/or an ejaculate from a male human being.
Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
Type:
Application
Filed:
August 4, 2011
Publication date:
December 1, 2011
Applicants:
HVIDOVRE HOSPITAL, RIGSHOSPITALET
Inventors:
Mads Nikolaj Holten-Andersen, Ib Jarle Christensen, Nils Brünner, Hans Jørgen Nielsen
Abstract: The present invention relates to a composition comprising: a) 0.01-20% wt/wt acetic acid and b) a physiologically tolerable buffer capable of maintaining acetic acid at a pH in the range of 2-7; and use of such a composition as an antimicrobial agent.
Type:
Application
Filed:
June 23, 2009
Publication date:
October 6, 2011
Applicants:
DANMARKS TEKNISKE UNIVERSITET, BISPEBJERG HOSPITAL, RIGSHOSPITALET COPENHAGEN UNIVERTISY HOSPITAL
Inventors:
Michael Christian Givskov, Thomas Bjarnsholt, Preben Homoe, Niels Hoiby, Peter Østrup Jensen, Helle Krogh Johansen, Klaus Kirketerp-Moller
Abstract: The present invention relates to the method of measuring the YKL-40 level and using this measurement as a prognosis for survival of an individual suffering from heart disease caused by atherosclerosis. The method may be used for classification of individuals in order to optimize treatment or monitoring the individuals during the course of or prior to or after treatment. The individual may suffer from any type of cardiovascular disease or disorder. The method also detects and determines whether diagnostically or prognostically significant levels of YKL-40 molecules are present in a biological sample. Furthermore the level of YKL-40 may be used to predict disease relapse.
Abstract: The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
Type:
Application
Filed:
August 30, 2010
Publication date:
March 10, 2011
Applicant:
RIGSHOSPITALET
Inventors:
Mads Holten-Andersen, Ross W. Stephens, Hans Jørgen Nielsen, Ib Jarle Christensen, Nils Brünner
Abstract: The present invention relates to methods of diagnosing the presence of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above a reference level indicates the presence of a non-specific disease or disorder. The subject may suffer from a variety of diseases or disorders. The reference level may be a reference level obtained from healthy individuals or it may be a previous measurement obtained from the same subject. The present invention furthermore relates to a method for classifying the severity of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above or below one or more reference levels gives the severity of said non-specific disease or disorder. The present invention further relates to a kit and a device that may be used in the method of the present invention comprising means for measuring the level of YKL-40 in a sample; and means for comparing the measured level of YKL-40 with at least one reference level of YKL-40.
Abstract: The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
Type:
Grant
Filed:
June 9, 2006
Date of Patent:
October 5, 2010
Assignee:
Rigshospitalet
Inventors:
Mads Holten-Andersen, Ross Stephens, Hans Jørgen Nielsen, Ib Jarle Christensen, Nils Brünner
Abstract: Disclosed is a developmental animal model of temporal lobe epilepsy and other seizure-related disorders. In particular, the invention provides a method of inducing a permanent change in the neurological development of a rodent, such as a rat, comprising daily administration of low doses of a kainate receptor agonist to the animal in the second postnatal week, wherein after treatment with the kainate receptor agonist the animal exhibits reproducible seizure-like symptoms when exposed to mild to moderate stressors. Rats treated using the above method are particularly useful as a non-human system for studying temporal lobe epilepsy, as well as for studying the efficacy of potential anti-epileptic compounds and pharmaceutical preparations.
Type:
Grant
Filed:
April 6, 2006
Date of Patent:
November 24, 2009
Assignee:
H:S Rigshospitalet
Inventors:
Tracey Doucette, Henriette Husum Bak-Jensen, Melissa Perry, Catherine Ryan, R. Andrew Tasker
Abstract: Disclosed is a developmental animal model of temporal lobe epilepsy and other seizure-related disorders. In particular, the invention provides a method of inducing a permanent change in the neurological development of a rodent, such as a rat, comprising daily administration of low doses of a kainate receptor agonist to the animal in the second postnatal week, wherein after treatment with the kainate receptor agonist the animal exhibits reproducible seizure-like symptoms when exposed to mild to moderate stressors. Rats treated using the above method are particularly useful as a non-human system for studying temporal lobe epilepsy, as well as for studying the efficacy of potential anti-epileptic compounds and pharmaceutical preparations.
Type:
Grant
Filed:
April 6, 2006
Date of Patent:
April 21, 2009
Assignees:
University of Prince Edward Island, H:S Rigshospitalet
Inventors:
Tracy Doucette, Henriette Husum Bak-Jensen, Melissa Perry, Catherine Ryan, R. Andrew Tasker
Abstract: The invention relates to a method for screening and/or detecting and/or monitoring a cancer in an individual, said method comprising determining a first parameter represented by the concentration of TIMP-1 in at least one excreta, e.g. saliva, from the individual. The invention provides a method that without the need to use a blood sample is suitable for facilitating the early diagnosis of a cancer, monitoring the recurrence of a cancer, and/or monitoring the status of a cancer or the effect of cancer treatment in an individual.
Type:
Application
Filed:
August 7, 2008
Publication date:
February 5, 2009
Applicant:
Rigshospitalet, Public University Hospital
Inventors:
Lasse L. Hessel, Jesper Malling, Nils Brunner, Mads Holten-Andersen, Hans Jorgen Nielsen
Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
Type:
Application
Filed:
April 11, 2008
Publication date:
October 23, 2008
Applicants:
RIGSHOSPITALET, HVIDOVRE HOSPITAL
Inventors:
Mads Nikolaj Holten-Andersen, Ib Jarle Christensen, Nils Brunner, Hans Jorgen Nielsen
Abstract: The present invention relates to methods and kits for detecting several polynucleotide sequence found to be indicative of a poor prognosis of B-CLL. All the polynucleotides are transcribed from a region on human chromosome 12p21-22. Most of the polynucleotides do not encode larger polypeptides, but may encode small peptides, they may function as RNAs. Four polynucleotides encode a novel protein, which in one preferred embodiment can be used as a cytokine, preferably as an interleukin. Furthermore the invention relates to methods and compositions for treating B-CLL in particular poor prognosis B-CLL.
Type:
Application
Filed:
August 30, 2007
Publication date:
July 31, 2008
Applicants:
H:S RIGSHOSPITALET, ÁRHUS UNIVERSITET
Inventors:
Anne Mette Buhl HERTZ, Henrik LEFFERS, Jorgen KJEMS
Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
Type:
Grant
Filed:
April 8, 2002
Date of Patent:
May 20, 2008
Assignees:
Rigshospitalet, Hvidovre Hospital
Inventors:
Mads Nikolaj Holten-Andersen, Ib Jarle Christensen, Nils Brünner, Hans Jørgen Nielsen
Abstract: The present invention describes a method for determining whether an individual is likely to have cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
Type:
Application
Filed:
June 9, 2006
Publication date:
January 25, 2007
Applicant:
Rigshospitalet
Inventors:
Mads Holten-Andersen, Ross Stephens, Hans Jorgen Nielsen, Ib Christensen, Nils Brunner
Abstract: The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
Type:
Grant
Filed:
April 10, 2000
Date of Patent:
September 19, 2006
Assignee:
Rigshospitalet
Inventors:
Mads N. Holten-Andersen, Ross W. Stephens, Hans Jorgen Nielsen, Ib Jarle Christensen, Nils Brünner
Abstract: The invention relates to a method for screening and/or detecting and/or monitoring a cancer in an individual, said method comprising determining a first parameter represented by the concentration of TIMP-1 in at least one excreta, e.g. saliva, from the individual. The invention provides a method that without the need to use a blood sample is suitable for facilitating the early diagnosis of a cancer, monitoring the recurrence of a cancer, and/or monitoring the status of a cancer or the effect of cancer treatment in an individual.
Type:
Application
Filed:
March 28, 2005
Publication date:
July 13, 2006
Applicants:
Rigshospitalet, Hvidovre Hospital
Inventors:
Lasse Hessel, Jesper Malling, Nils Brunner, Mads Holten-Andersen, Hans Nielsen